Crizotinib demonstrated an association with a sharp increase in survival rates for patients with advanced non-small cell lung cancer with an anaplastic lymphoma kinase positive genetic alteration, according to the results of a study presented at the annual meeting of the American Society of Clinical Oncology.
Crizotinib, an investigational drug, demonstrated an association with a sharp increase in survival rates for patients with advanced non-small cell lung cancer (NSCLC) with an anaplastic lymphoma kinase (ALK) positive genetic alteration, according to the results of an early-phase study presented at the 2011 annual meeting of the American Society of Clinical Oncology.
To determine the impact of crizotinib on overall survival of patients with ALK+ NSCLC, researchers examined survival of 82 ALK-positive patients who enrolled in the expansion cohort of the phase 1 trial of crizotinib. Thirty-seven NSCLC ALK-positive patients from phase 1 sites who were not treated with crizotinib (ALK-positive controls) and 253 NSCLC ALK/epidermal growth factor receptor patients from 1 site (ALK- controls) were identified as comparators.
One-year overall survival for the 82 ALK-positive patients treated with crizotinib was 77% and 2-year overall survival was 64%. Among the 37 ALK-positive controls, 1-year overall survival was 73%; while 2-year overall survival was 33%.
Additional studies presented at the meeting also looked at efficacy, safety, and tolerability of the drug. A continuation of the study above reported updated safety and response data and preliminary progression free survival data, finding that the efficacy of crizotinib in patients with ALK-positive NSCLC was “robust, rapid, durable and clinically meaningful.” The most common adverse events included vision disorder and gastrointestinal events, such as nausea, diarrhea, and vomiting. These adverse effects typically had early onset and diminished as the treatment continued.
In another ongoing study 83% of patients had target lesion shrinkage, while 54% had their tumors shrink by 30% or more. The most frequent treatment-related adverse events were mild and included nausea, vision disorder, vomiting, and diarrhea; however 2 of 9 deaths during the study were considered treatment related. Researchers concluded that crizotinib was safe and well-tolerated, and preliminary evidence indicated improved symptoms and clinically meaningful antitumor activity.
Pfizer announced last month that it filed a new drug application with FDA for approval of crizotinib in patients with advanced NSCLC whose tumors express the EML4-ALK fusion oncogene. FDA has granted the drug fast-track designation.
With regard to the expansion cohort phase 1 trial that enrolled the 82 ALK-positive patients, Alice Shaw, MD, PhD of the Massachusetts General Hospital Cancer Center and an author of the findings was quoted as saying in the NCI Cancer Bulletin: “This trial confirms what we have known from the very first patient-that this drug is a great option for these patients.” She added that little is known about the natural history of this particular type of lung cancer and additional research is needed, according to the online publication.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.